FATE

$2.04+1.49%visit website

FATE THERAPEUTICS INC

Market Cap

$244M

Live price × SEC shares (Aug 6, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

2.62

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

37.7

TTM to Jun 2026 · revenue

P/B

1.6

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	1,741	1,369	1,299	2,082	6,491
Research & development	25,838	25,425	24,703	24,387	100,353
Total operating expenses	36,476	36,090	34,299	33,216	140,081
Operating income	(34,735)	(34,721)	(33,000)	(31,134)	(133,590)
Net income	(32,250)	(32,374)	(31,213)	(30,159)	(125,996)
EPS (basic) ($)	(0.27)		(0.26)	(0.25)	(1.05)
EPS (diluted) ($)	(0.27)		(0.26)	(0.25)	(1.05)
Weighted avg. shares (basic)	118,999		120,031	120,397
Weighted avg. shares (diluted)	118,999		120,031	120,397

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 13, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 54 more quarters, back to Mar 2012, with Tormere Pro.

Corporate Events (8-K)

7 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Sep 28, 2026 accepted 8:10 AM ET	8.01Other events	Document SEC ↗
Aug 13, 2026 accepted 8:31 AM ET	2.02Earnings release	Document SEC ↗
Jun 15, 2026 accepted 4:02 PM ET	5.02Officer / director change5.07Shareholder vote	Document SEC ↗
Jun 4, 2026 accepted 4:37 PM ET	8.01Other events	Document SEC ↗
May 13, 2026 accepted 8:32 AM ET	2.02Earnings release	Document SEC ↗
Feb 26, 2026 accepted 9:04 AM ET	2.02Earnings release	Document SEC ↗
Nov 13, 2025 accepted 8:32 AM ET	2.02Earnings release	Document SEC ↗
Oct 27, 2025 accepted 7:00 AM ET	7.01Reg FD disclosure8.01Other events	Document SEC ↗
Oct 14, 2025 accepted 4:02 PM ET	5.02Officer / director change7.01Reg FD disclosure	Document SEC ↗
Aug 12, 2025 accepted 4:07 PM ET	2.02Earnings release2.05Restructuring costs	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

34%

W/W -18.2pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-08-04	2026-08-05	Valamehr Bahram	Director & President and CEO	Sale	43.9K	$2.46	$108K	591.8K	View
2026-08-04	2026-08-05	TAHL CINDY	See Remarks	Sale	38.8K	$2.46	$95K	589.4K	View
2026-05-20	2026-05-21	TAHL CINDY	See Remarks	Sale	25.6K	$1.88	$48K	628.2K	View
2026-05-20	2026-05-21	Valamehr Bahram	Director & President and CEO	Sale	28.9K	$1.88	$54K	635.8K	View
2026-01-09	2026-01-12	Valamehr Bahram	Director & President and CEO	Sale	5,190	$1.07	$6K	329.7K	View

1–5 of 6

1 / 2

Recent News

US Midterm Elections: 3 Scenarios That Could Decide Dalal Street's Fate

NDTV · 2026-11-04

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Yahoo · 2026-11-03

Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Has Average Target Price of $5.90 According to Analysts

MarketBeat · 2026-11-03

FATE Nov 2026 0.500 put (FATE261120P00000500) Stock Price, News, Quote & History

Yahoo! Finance Canada · 2026-11-02

These Senate races may help determine the fate of Social Security

CNBC · 2026-11-01

Two fears will decide the fate of Anthropic’s giant IPO

Financial Times · 2026-10-29

No clear winner in Israeli election, exit polls suggest, as Netanyahu’s fate hangs in the balance

CNBC · 2026-10-27

Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

Benzinga · 2026-10-27

Fate Therapeutics, Inc. (FATE) stock price, news, quote and history

Yahoo Finance Singapore · 2026-10-27

Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026

Yahoo · 2026-10-26

Fate Therapeutics Presents Updated Phase 1 Clinical Data For FT819, Off-The-Shelf, Available On-Demand, Anti-CD19 CAR T-Cell Product Candidate, In Patients With SLE With Lupus Nephritis At ASN Kidney Week 2026

Benzinga · 2026-10-26

Putin reportedly suggests summit with Trump and Xi to decide fate of Ukraine

CNBC · 2026-10-19

Fate Therapeutics, Inc. Stock 12‑Month Price Target Cut to $6.07, Implies 215% Upside

TradingView · 2026-10-15

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

Yahoo · 2026-10-12

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

Yahoo Finance · 2026-10-01

Informational purposes only, not investment advice.

FATE

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

FATE THERAPEUTICS INC (FATE)

Reporting Insiders

Factor Profile

Corporate Events (8-K)

Date	Insider	Type	Shares	Value
2026-08-04	Valamehr Bahram	S	43,947	$108,100.83
2026-08-04	TAHL CINDY	S	38,800	$95,405.32
2026-05-20	TAHL CINDY	S	25,590	$48,083.61
2026-05-20	Valamehr Bahram	S	28,946	$54,482.16
2026-01-09	Valamehr Bahram	S	5,190	$5,557.45